Clinical Value of Monitoring Plasma Octreotide Levels During Chronic Octreotide Long-Acting Repeatable Therapy in Carcinoid Patients

Woltering EA, Salvo VA, O’Dorisio TM, Lyons J 3rd, Li G, Zhou Y, Seward JR, Go VL, Vinik AI, Mamikunian P, Mamikunian G.

Department of Surgery, Louisiana State University Health Sciences Center, New Orleans, LA, USA.

Pancreas. 2008 Jul; 37(1): 94-100

Conclusion: Current plasma octreotide values are significantly lower than previously reported for 30-, 60-, and 120-mg/mo LAR doses. Serial plasma octreotide value measurements should be used to determine if increasing symptoms or tumor growth are associated with suboptimal drug dosing.

  • Improving Worldwide Cancer Care and Prevention Awareness

Oncology by PracticeUpdate

PracticeUpdate’s mission is to connect healthcare professionals with news and information that matters most for patient care. The site is tailored to deliver the latest expert curated content based on the clinician’s area of practice, and is optimized for viewing on any device. Individual access to PracticeUpdate is free, based upon users registering with the site.

TIP: for example, type “neuroendocrine tumors” (or other cancers) in the search window and you will receive a comprehensive list of up-to-date peer-review articles of neuroendocrine tumors from  cancer-related journals, including The Lancet Oncology, New England Journal of Medicine, Journal of Clinical Oncology, etc. Many articles are full text.



Print Friendly, PDF & Email